Ann Arbor, Michigan, May 14th, 2015: TSRL Inc., a pharmaceutical company developing novel anti-infective therapeutics in areas of high unmet medical need, is pleased to announce that Elke Lipka, PhD, MBA, has presented at the 28th International Conference on Antiviral Research (ICAR) in Rome, Italy. The presentation, entitled "Potent Broad Spectrum Anti-DNA Viral Activity for HPMPA and HPMPC Tyrosinamide Prodrugs", reports on the broad spectrum antiviral activity of acyclic nucleoside phosphonates (ANPs) as useful agents in the treatment of many DNA virus infections.
About TSRL, Inc.
TSRL, Inc. is a privately-held anti-infectives drug development firm and accelerator focused on R&D efforts to optimize effectiveness and safety of investigational and marketed therapeutics. More information about TSRL, Inc. is available on the company website www.tsrlinc.com or can be requested by contacting Dr. Elke Lipka, President, 734 663-4233 x236, firstname.lastname@example.org.